Effect of Intravenous Flecainide on Atrial Vulnerability in Man T. Pop II.N. Treese Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 1 - 6
Clinical Usefulness of Flecainide Acetate in the Treatment of Paroxysmal Supraventricular Arrhythmias A. John. CammA. CammRodney S. Bexton Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 7 - 13
Comparative Evaluation of Àntiarrhythmic Agents Joel Morganroth Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 14 - 20
Long Term Use of Flecainide in Patients with Supraventricular Tachycardia H. Neuss Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 21 - 25
Experience in the Long Term Use of New Antiarrhythmic Drugs T. MeinertzM. K. ZehenderT. Pop Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 26 - 27
The Clinical Use of Oral Flecainide R. SlamaJ. F. LeClercq Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 28 - 29
Aggravation of Ventricular Arrhythmia Philip J. Podrid Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 33 - 44
The Proarrhythmic Effects of Flecainide Anthony W. NathanKevin J. HellestrandA. John Camm Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 45 - 53
Haemodynamic Effects of Class I Antiarrhythmic Agents Victor LegrandPierre Collignon Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 54 - 57
Haemodynamic and Antiarrhythmic Effects of Intravenous Flecainide Acetate in Chronic Congestive Heart Failure Peter H. J. M. DunselmanJ. Herre KingmaK. I. Lie Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 58 - 64
Benefit-Risk Ratio in the Treatment of Tachyarrhythmias F. Bender Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 65 - 67
Logic and Empiricism in the Selection of Antiarrhythmic Agents Philippe CoumelFabrice ChoutyRobert Slama Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 68 - 76
Antiarrhythmic Therapy with Flecainide in Combination and Comparison with Propranolol H. SternM. ScheiningerK. Theisen Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 77 - 85
Comparative Evaluation of Antiarrhythmic Therapy L. KappenbergerP. J. Schwartz Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 86 - 86